Search the Newsreel

Regeneron ends eye disease study due to antibody’s safety profile

Regeneron has discontinued a Phase 1/2 study for REGN7041, an investigational anti-inflammatory antibody for non-infectious uveitis, due to an unfavorable benefit-risk assessment following an unspecified safety event. This setback adds to a series of recent clinical trial failures for Regeneron, increasing pressure from analysts …

Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet

Takeda Pharmaceutical Co. (TAK) closed the last trading session at $17.38, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price …

Amylyx Pharmaceuticals (NASDAQ:AMLX) Hits New 12-Month High Following Analyst Upgrade

Amylyx Pharmaceuticals (NASDAQ:AMLX) reached a new 52-week high after Mizuho raised its price target from $24 to $30 and maintained an outperform rating. The stock traded as high as $28.95 and closed at $29.8120, with a consensus "Moderate Buy" rating from analysts. Despite missing …

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia (PBH). The trial met its primary endpoint, showing a 55% reduction in hypoglycemic events, and all secondary endpoints. Amylyx plans to submit a New Drug Application …

BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca

BioMarin Pharmaceutical has acquired Alesta Therapeutics for an upfront payment of $275 million, with an additional $215 million in potential milestones. This acquisition aims to position BioMarin to compete with AstraZeneca in the rare bone disease market, specifically hypophosphatasia (HPP), with Alesta's oral drug …

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

Bernstein Liebhard LLP has announced a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements, leading to …

BioMarin stock surges on $275M Alesta acquisition deal

BioMarin Pharmaceutical Inc. announced its acquisition of Alesta Therapeutics for $275 million upfront, causing BioMarin's shares to rise by 4.7% in premarket trading. The deal grants BioMarin access to ALE1, an oral therapy for hypophosphatasia (HPP) currently in clinical trials, with potential additional payments …

Eyepoint Pharmaceuticals' (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank of Canada reiterated its "sector perform" rating for EyePoint Pharmaceuticals (EYPT) but significantly cut its price target to $5 from $37, citing uncertainty after the DURAVYU Phase 3 LUGANO trial missed its primary endpoint. Despite this, other analysts remain divided, with some …

Why Medipharm Labs Corp stock surged yesterday

Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock

Rocket Pharmaceuticals CEO Gaurav Shah sold 2,837 shares of company stock worth $9,591 to cover tax obligations from vested Restricted Stock Units. Despite this sale, Shah retains significant holdings. The company also recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million …

BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

BTIG Research has reaffirmed a "Buy" rating for NRx Pharmaceuticals (NASDAQ:NRXP) and set a $10 price target, suggesting a potential upside of 191.55% from its current price of $3.43. This comes despite NRx Pharmaceuticals reporting a quarterly loss of $0.44 per share and revenue …

ABVC BioPharma (ABVC) Slides 5.56% to $0.85 as Micro-Cap Biotech Faces Selling Pressure - Gap Fill Strategy

MDCX Q1 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Revenue Guidance Range

TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00

HC Wainwright & Co. has reiterated a Neutral rating for Traws Pharma Inc (TRAW), maintaining a price target of $1.00. Despite a GF Value™ indicating the stock is significantly undervalued at $13.05 compared to its current price of $0.54, the company's low GF Score™ …

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the spinout entity prior to close ALE1 has significant potential to …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Earns Neutral Rating from HC Wainwright

What is HC Wainwright's Estimate for AVBP FY2027 Earnings?

HC Wainwright has issued an estimate for ArriVent BioPharma's (NASDAQ: AVBP) FY2027 earnings per share at ($4.24), maintaining a "Buy" rating and a $47 price target. This target is above the analyst consensus of $44.86. The company recently reported a Q2 EPS of ($1.05), …

Crinetics Pharmaceuticals (CRNX) Stock Looks Overvalued Despite Strong 3 Year Returns

Crinetics Pharmaceuticals (CRNX) has shown strong returns over the past three years, but its current valuation, particularly its P/B ratio of 7.5x compared to an industry average of 2.5x, suggests it is overvalued. Despite a mixed overall valuation profile, the market appears to be …

Amylyx posts late-stage trial win for GLP-1 drug (AMLX:NASDAQ)

Amylyx Pharmaceuticals (AMLX) announced positive results from its Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist. The drug successfully met its main goals in patients experiencing low blood sugar after gastric bypass surgery. This news led to a surge in Amylyx's stock.

HC Wainwright Predicts Higher Earnings for Zenas BioPharma

HC Wainwright has revised its Q3 2026 EPS estimate for Zenas BioPharma (NASDAQ: ZBIO) to a loss of $1.31 per share, an improvement from its prior estimate of a $1.46 loss, while maintaining a "Buy" rating. Despite this positive revision, Zenas BioPharma recently reported …

PharmX (ASX:PHX) Strengthens Healthcare Technology Platform Through Supplier and Pharmacy Expansion

HC Wainwright Analysts Increase Earnings Estimates for RIGL

HC Wainwright analysts have increased their Q3 2026 earnings per share estimate for Rigel Pharmaceuticals (NASDAQ:RIGL) to $0.99 from $0.68, maintaining a "Buy" rating and an $85 price target. This revision follows Rigel's strong quarterly results, where EPS of $0.88 significantly beat the $0.09 …

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST)

Milestone Pharmaceuticals (MIST) is reiterated as a 'Sell' due to the weak differentiation of its product, CARDAMYST, and its poor commercial uptake compared to low-cost generics. The company's financial health is deteriorating with low revenue, heavy discounting, minimal payer coverage, and increasing liabilities. Despite …

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile

Regeneron has terminated a Phase 1/2 study of its investigational anti-inflammatory antibody, REGN7041, for non-infectious uveitis due to an "unfavorable benefit-risk assessment." This marks another clinical setback for Regeneron, following failures of itepekimab for COPD and a melanoma combo. Despite these challenges, the company, …

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

The article discusses Agios Pharmaceuticals' cash burn rate, expressing a lack of significant concern despite the company operating at a loss. It likely details the company's financial position, how its cash reserves compare to its burn, and the market's perception of its financial health.

H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1

H.C. Wainwright has reiterated a Neutral rating and a $1.00 price target on Traws Pharma (NASDAQ:TRAW) following the company's Q2 2026 update. The company is working to resubmit an updated toxicology package to the MHRA and resolve a U.S. clinical hold, as its TXM …

Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News

Rhythm Pharmaceuticals (RYTM) has seen a significant 5-year return, but its current valuation, particularly its high P/S ratio of 33.1x, suggests it may be overvalued compared to the biotech industry average and its own tailored fair P/S ratio of 19.7x. While recent positive news …

Teva doubles over 52 weeks, but negative pressure clouds a near-high close

The ADR finished the week at $36.77, just 1.7% below its 52-week high, with trend and relative strength intact but volume confirmation still modest.

Sichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions

Lee’s Pharmaceutical Sets Board Meeting to Review 2026 Interim Results and Dividend

Is First EU REDEMPLO Approval in FCS Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation

Mereo BioPharma Group (NASDAQ:MREO) has a cash runway of about 14 months based on its current cash burn of US$25 million against US$30 million in reserves. Analysts project the company will reach breakeven before this period, and its cash burn has decreased by 24% …

Amylyx's experimental drug cut dangerous low-blood-sugar events by 55%

Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial for avexitide, an experimental drug for post-bariatric hypoglycemia (PBH). The trial showed a 55% reduction in severe hypoglycemic events compared to placebo, meeting its primary endpoint. Amylyx plans to submit a …

Amylyx’s bet on a GLP-1 blocker pays off

Amylyx Pharmaceuticals reported positive results from a late-stage clinical trial for avexitide, a GLP-1 blocker designed to treat dangerously low blood sugar levels in patients who have undergone bariatric surgery. The drug significantly reduced hypoglycemic events and appeared safe, leading Amylyx to plan for …

Lead Plaintiff Deadlines in Shareholder Class Action

Holzer & Holzer, LLC is reminding investors of upcoming lead plaintiff deadlines in class action lawsuits against ARS Pharmaceuticals, Inc. (SPRY), Alarum Technologies Ltd. (ALAR), and HDFC Bank Limited (HDB). Investors who purchased shares in these companies during specified periods and suffered losses are …